New insights into T-cell acute lymphoblastic leukaemia development – Medical Xpress

May 30, 2017

A research team from the National University of Singapore (NUS) led by Assistant Professor Takaomi Sanda, Principal Investigator from the Cancer Science Institute of Singapore and Department of Medicine at NUS Yong Loo Lin School of Medicine, has provided new insights into the molecular mechanism affecting how genes are produced during normal T-cell development, and contributing to leukaemia formation. Results of the study have been published in the journal Leukemia.

T-cells are a type of white blood cell which develops in the thymus (hence the name T-cell), a primary lymphoid organ. These cells play an indispensable role in the body's cellular defence system. In T-cell acute lymphoblastic leukaemia (T-ALL), which is a cancer of the white blood cells, T-cells carry genetic mutations which cause them to multiply uncontrollably. Production of genes during T-cell development is strictly controlled by the body. Different genes are turned 'on' and 'off' at various stages of T-cell development, in order to ensure T-cells become fully functional in the immune system.

TAL1 triggers the super-enhancer 'switch'

Specifically, the research team studied the protein TAL1, which is encoded by a cancer causing gene previously found to contribute to the development of T-ALL, and discovered that TAL1 activates a 'molecular switch' called a super-enhancer, which subsequently leads to a cluster of genes called GIMAP being activated. This may result in T-cell precursors growing abnormally and not developing into functional T-cells in the body, leading to the development of T-ALL.

Super-enhancers are regions of DNA that increase production of genes linked to important cellular decisions. They can be sensitive to disturbances and occur frequently at cancer genes. The activation of the super-enhancer induces genes to be abnormally activated, instead of being strictly controlled.

Asst Prof Sanda said, "Currently, most of the patients with T-ALL are young children. While recent improvements in chemotherapy have significantly boosted cure rates for T-ALL, the introduction of intensive chemotherapy causes both short- and long-term adverse effects. Moreover, there are only a limited number of new drugs with specific activity against malignant T-cells. Moving forward, we are looking into identifying potential therapeutic compounds that inhibits the activation of this super-enhancer. We hope to be able to translate it into meaningful therapies for patients afflicted by T-ALL."

Explore further: Preventing too much immunity

More information: W S Liau et al. Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia, Leukemia (2016). DOI: 10.1038/leu.2016.392

Scientists at the Immunology Frontier Research Center (IFReC), Osaka University, Japan, report a new molecular mechanism that could explain the cause of some autoimmune diseases.

Genetic mutations can increase a person's cancer risk, but other gene "enhancer" elements may also be responsible for disease progression, according to new research out of Case Western Reserve University School of Medicine. ...

A person's genetic makeup plays a role in autoimmune diseases such as multiple sclerosis that develop when the body is attacked by its own immune system. But little is known about how immune cells are pushed into overdrive.

In cells, DNA is transcribed into RNAs that provide the molecular recipe for cells to make proteins. Most of the genome is transcribed into RNA, but only a small proportion of RNAs are actually from the protein-coding regions ...

New insights into a gene linked to the development of blood cancers could help to explain why some patients are resistant to a common drug used in cancer treatment.

Research in the field of kidney cancer, also called renal cancer, is vital, because many patients with this disease still cannot be cured today. Researchers from the University of Zurich have now identified some of the gene ...

A University of Otago, Christchurch, discovery of missing DNA in women who develop breast cancer at a young age could hold the key to helping them beat the disease.

In a new study, scientists at The University of Texas at Dallas have found that some types of cancers have more of a sweet tooth than others.

Earlier this week, for the first time, a drug was FDA-approved for cancer based on disease genetics rather than type.

Melanoma is a particularly difficult cancer to treat once it has metastasized, spreading throughout the body. University of Illinois researchers are using chemistry to find the deadly, elusive malignant cells within a melanoma ...

A team led by Johns Hopkins researchers has discovered a biochemical signaling process that causes densely packed cancer cells to break away from a tumor and spread the disease elsewhere in the body. In their study, published ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Here is the original post:
New insights into T-cell acute lymphoblastic leukaemia development - Medical Xpress